8-K Announcements
6Material company update
Feb 17, 2026·SEC
Material company update
Jan 22, 2026·SEC
Material company update
Dec 29, 2025·SEC
Ekso Bionics Holdings, Inc.(EKSO)Earnings, Financials & Key Ratios
EKSO•NASDAQ
Price updated Jun 19, 2026
AboutEkso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.Show more
- Revenue$13M-28.6%
- EBITDA-$12M-32.8%
- Net Income-$12M-3.2%
- EPS (Diluted)-4.91-776.8%
- Gross Margin53.48%+0.8%
- EBITDA Margin-91.83%-85.9%
- Operating Margin-104.12%-78.4%
- Net Margin-91.37%-44.6%
- ROE-107.62%-20.2%
EKSO Key Insights
Ekso Bionics Holdings, Inc. (EKSO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Share count reduced 88.0% through buybacks
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EKSO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EKSO Price & Volume
Ekso Bionics Holdings, Inc. (EKSO) stock price & volume — 10-year historical chart
Loading chart...
EKSO Growth Metrics
Ekso Bionics Holdings, Inc. (EKSO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.98%
5 Years7.58%
3 Years-0.29%
TTM-34.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1022.92%
Return on Capital
10 Years-94.33%
5 Years-57.38%
3 Years-65.7%
Last Year-87.13%
EKSO Recent Earnings
Ekso Bionics Holdings, Inc. (EKSO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 23, 2026Metric
Actual
Est
EPS
$1.56-1850.0%
$0.08
Rev
$3M-37.5%
$5M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.54+45.5%
$0.99
Rev
$4M-15.9%
$5M
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$1.24-3.3%
$1.20
Rev
$2M-50.4%
$4M
Q2 2025
May 5, 2025Metric
Actual
Est
EPS
$1.80-9.1%
$1.65
Rev
$3M-38.7%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 23, 2026 | $1.56vs $0.08-1850.0% | $3Mvs $5M-37.5% |
| Q4 2025 | Oct 28, 2025 | $0.54vs $0.99+45.5% | $4Mvs $5M-15.9% |
| Q3 2025 | Jul 28, 2025 | $1.24vs $1.20-3.3% | $2Mvs $4M-50.4% |
| Q2 2025 | May 5, 2025 | $1.80vs $1.65-9.1% | $3Mvs $6M-38.7% |
Based on last 12 quarters of dataView full earnings history →
EKSO Peer Comparison
Ekso Bionics Holdings, Inc. (EKSO) competitors in Rehabilitation and mobility aids — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IRBT | 1.72M | 0.05 | -0.01 | -23.44% | -38.16% | -112.92% | 3.71 | |
 CYBR | 20.64B | 408.85 | -139.54 | 36.01% | -10.79% | -6.11% | 0.51 | |
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 MYO | 49.46M | 1.28 | -3.46 | 25.73% | -36.69% | -114.87% | 1.70 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 MASI | 9.42B | 179.95 | -64.27 | -27.1% | 4.9% | 9.08% | 0.78 |
Compare EKSO vs Peers
Ekso Bionics Holdings, Inc. (EKSO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EKSO Income Statement
Ekso Bionics Holdings, Inc. (EKSO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.35M | 11.33M | 13.92M | 8.88M | 11.25M | 12.91M | 18.28M | 17.93M | 12.8M | 11.56M |
Revenue Growth % | -48.29% | 54.11% | 22.81% | -36.18% | 26.62% | 14.81% | 41.57% | -1.94% | -28.6% | -34.08% |
Cost of Goods Sold | 5.28M | 7.02M | 7.15M | 3.81M | 4.5M | 6.7M | 9.2M | 8.41M | 5.95M | 5.45M |
COGS % of Revenue | 71.86% | 61.97% | 51.4% | 42.92% | 39.99% | 51.87% | 50.33% | 46.94% | 46.52% | - |
Gross Profit | 2.07M▲ 0% | 4.31M▲ 108.3% | 6.76M▲ 57.0% | 5.07M▼ 25.0% | 6.75M▲ 33.1% | 6.21M▼ 7.9% | 9.08M▲ 46.1% | 9.51M▲ 4.8% | 6.84M▼ 28.0% | 6.11M▲ 0% |
Gross Margin % | 28.14% | 38.03% | 48.6% | 57.08% | 60.01% | 48.13% | 49.67% | 53.06% | 53.48% | 52.86% |
Gross Profit Growth % | -29.79% | 108.26% | 56.97% | -25.04% | 33.12% | -7.93% | 46.11% | 4.76% | -28.03% | - |
Operating Expenses | 33.35M | 31.37M | 23.4M | 17.93M | 20.58M | 21.77M | 24.19M | 19.97M | 20.17M | 21.62M |
OpEx % of Revenue | 453.61% | 276.86% | 168.16% | 201.85% | 182.97% | 168.6% | 132.34% | 111.41% | 157.6% | - |
Selling, General & Admin | 23.87M | 25.53M | 18.81M | 15.45M | 17.83M | 18.14M | 19.17M | 16.1M | 17.14M | 18.99M |
SG&A % of Revenue | 324.64% | 225.26% | 135.14% | 173.99% | 158.54% | 140.52% | 104.85% | 89.8% | 133.92% | - |
Research & Development | 9.48M | 5.85M | 4.6M | 2.47M | 2.75M | 3.63M | 5.03M | 3.87M | 3.03M | 2.63M |
R&D % of Revenue | 128.97% | 51.6% | 33.02% | 27.85% | 24.44% | 28.08% | 27.49% | 21.61% | 23.68% | - |
Other Operating Expenses | 296K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -31.61M▲ 0% | -27.03M▲ 14.5% | -16.64M▲ 38.4% | -12.86M▲ 22.7% | -13.83M▼ 7.5% | -15.56M▼ 12.5% | -15.11M▲ 2.9% | -10.46M▲ 30.8% | -13.33M▼ 27.4% | -15.5M▲ 0% |
Operating Margin % | -429.92% | -238.53% | -119.56% | -144.76% | -122.96% | -120.48% | -82.67% | -58.35% | -104.12% | -134.06% |
Operating Income Growth % | -14.59% | 14.49% | 38.44% | 22.72% | -7.54% | -12.5% | 2.85% | 30.78% | -27.4% | - |
EBITDA | -29.88M | -25.53M | -15.95M | -12.24M | -13.27M | -14.67M | -13.41M | -8.85M | -11.75M | -14.31M |
EBITDA Margin % | -406.36% | -225.29% | -114.6% | -137.78% | -117.97% | -113.61% | -73.38% | -49.38% | -91.83% | -123.73% |
EBITDA Growth % | -16.12% | 14.56% | 37.53% | 23.27% | -8.41% | -10.57% | 8.56% | 34.01% | -32.77% | -44.26% |
D&A (Non-Cash Add-back) | 1.73M | 1.5M | 690K | 620K | 561K | 887K | 1.7M | 1.61M | 1.57M | 1.2M |
EBIT | -28.47M | -26.39M | -11.75M | -15.69M | -9.65M | -14.92M | -14.9M | -11.06M | -11.39M | -8.26M |
Net Interest Income | -648K | -600K | -1.48M | -139K | -113K | -156K | -302K | -269K | -309K | -547K |
Interest Income | 0 | 0 | 384K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 648K | 600K | 384K | 139K | 113K | 156K | 302K | 269K | 309K | 404K |
Other Income/Expense | 2.49M | 38K | 4.51M | -2.97M | 4.06M | 476K | -86K | -870K | 1.63M | -185K |
Pretax Income | -29.12M▲ 0% | -26.99M▲ 7.3% | -12.13M▲ 55.1% | -15.82M▼ 30.4% | -9.76M▲ 38.3% | -15.08M▼ 54.4% | -15.2M▼ 0.8% | -11.33M▲ 25.5% | -11.7M▼ 3.2% | -15.69M▲ 0% |
Pretax Margin % | -396.06% | -238.19% | -87.17% | -178.17% | -86.82% | -116.79% | -83.14% | -63.21% | -91.37% | -135.66% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -29.12M▲ 0% | -26.99M▲ 7.3% | -12.13M▲ 55.1% | -15.82M▼ 30.4% | -9.76M▲ 38.3% | -15.08M▼ 54.4% | -15.2M▼ 0.8% | -11.33M▲ 25.5% | -11.7M▼ 3.2% | -15.69M▲ 0% |
Net Margin % | -396.06% | -238.19% | -87.17% | -178.17% | -86.82% | -116.79% | -83.14% | -63.21% | -91.37% | -135.66% |
Net Income Growth % | -24.08% | 7.31% | 55.05% | -30.44% | 38.3% | -54.44% | -0.78% | 25.45% | -3.22% | -45.38% |
Net Income (Continuing) | -29.12M | -26.99M | -12.13M | -15.82M | -9.76M | -15.08M | -15.2M | -11.33M | -11.7M | -15.69M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -12.27▲ 0% | -6.61▲ 46.1% | -2.44▲ 63.1% | -2.21▲ 9.4% | -0.88▲ 60.2% | -1.16▼ 31.8% | -1.10▲ 5.2% | -0.56▲ 49.1% | -4.91▼ 776.8% | -4.40▲ 0% |
EPS Growth % | 35.08% | 46.13% | 63.09% | 9.43% | 60.18% | -31.82% | 5.17% | 49.09% | -776.79% | -1022.92% |
EPS (Basic) | -12.27 | -6.61 | -2.44 | -2.21 | -0.80 | -1.16 | -1.10 | -0.56 | -4.91 | - |
Diluted Shares Outstanding | 2.37M | 4.08M | 4.79M | 7.16M | 12.27M | 12.96M | 13.87M | 20.16M | 2.43M | 3.56M |
Basic Shares Outstanding | 2.37M | 4.08M | 4.79M | 7.16M | 12.19M | 12.96M | 13.87M | 20.16M | 2.43M | 3.56M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EKSO Balance Sheet
Ekso Bionics Holdings, Inc. (EKSO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 34.94M | 14.97M | 18.81M | 18.42M | 47.8M | 31.04M | 20.21M | 18.84M | 14.05M | 14.05M |
Cash & Short-Term Investments | 27.81M | 7.66M | 10.87M | 12.86M | 40.41M | 20.52M | 8.64M | 6.49M | 1.17M | 3.99M |
Cash Only | 27.81M | 7.66M | 10.87M | 12.86M | 40.41M | 20.52M | 8.64M | 6.49M | 1.17M | 3.99M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 2.76M | 3.66M | 5.21M | 3.39M | 4.66M | 4.63M | 5.64M | 7.24M | 7.31M | 4.54M |
Days Sales Outstanding | 137.01 | 117.89 | 136.59 | 139.27 | 151.31 | 130.74 | 112.72 | 147.38 | 208.41 | 176.95 |
Inventory | 3.02M | 3.37M | 2.49M | 1.98M | 2.24M | 5.19M | 5.05M | 4.57M | 4.82M | 4.65M |
Days Inventory Outstanding | 208.96 | 175.2 | 127.01 | 189.39 | 181.97 | 282.66 | 200.35 | 198.29 | 295.6 | 333.62 |
Other Current Assets | 1.34M | 281K | 238K | 191K | 0 | 700K | 875K | 541K | 750K | 874K |
Total Non-Current Assets | 3.05M | 2.69M | 3.11M | 2.18M | 1.37M | 9.87M | 8.71M | 7.81M | 6.06M | 5.62M |
Property, Plant & Equipment | 2.25M | 2.37M | 2.74M | 1.86M | 1.21M | 3.99M | 3M | 2.37M | 1.82M | 1.46M |
Fixed Asset Turnover | 3.27x | 4.79x | 5.08x | 4.78x | 9.32x | 3.24x | 6.10x | 7.58x | 7.03x | 6.33x |
Goodwill | 189K | 189K | 189K | 0 | 0 | 431K | 431K | 431K | 431K | 431K |
Intangible Assets | 491K | 0 | 0 | 0 | 0 | 5.22M | 4.89M | 4.58M | 3.5M | 3.42M |
Long-Term Investments | 0 | 0 | 36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 122K | 134K | 142K | 320K | 164K | 231K | 392K | 433K | 311K | 308K |
Total Assets | 37.99M▲ 0% | 17.66M▼ 53.5% | 21.91M▲ 24.1% | 20.6M▼ 6.0% | 49.17M▲ 138.7% | 40.9M▼ 16.8% | 28.92M▼ 29.3% | 26.65M▼ 7.8% | 20.11M▼ 24.5% | 19.67M▲ 0% |
Asset Turnover | 0.19x | 0.64x | 0.64x | 0.43x | 0.23x | 0.32x | 0.63x | 0.67x | 0.64x | 0.55x |
Asset Growth % | 55.53% | -53.52% | 24.13% | -6.01% | 138.7% | -16.81% | -29.3% | -7.84% | -24.54% | -92.51% |
Total Current Liabilities | 9.16M | 10.13M | 7.83M | 4.97M | 6.86M | 9.2M | 8.12M | 7.54M | 8.64M | 9.09M |
Accounts Payable | 2.42M | 3.16M | 1.9M | 1.5M | 3.11M | 3.15M | 1.85M | 1.55M | 1.43M | 2.11M |
Days Payables Outstanding | 167.16 | 164.02 | 97.11 | 143.72 | 252.18 | 171.71 | 73.28 | 67.33 | 87.73 | 111.28 |
Short-Term Debt | 2.14M | 2.33M | 2.77M | 548K | 0 | 2.31M | 1.25M | 1.25M | 1.69M | 3.33M |
Deferred Revenue (Current) | 1.1M | 1.1M | 1.49M | 1.5M | 1.22M | 1.12M | 1.99M | 1.96M | 1.73M | 6.82M |
Other Current Liabilities | 1.24M | 1.06M | 567K | 235K | 0 | 0 | 606K | 0 | 3.79M | 0 |
Current Ratio | 3.81x | 1.48x | 2.40x | 3.70x | 6.97x | 3.37x | 2.49x | 2.50x | 1.63x | 1.55x |
Quick Ratio | 3.48x | 1.14x | 2.08x | 3.31x | 6.65x | 2.81x | 1.87x | 1.89x | 1.07x | 1.03x |
Cash Conversion Cycle | 178.8 | 129.06 | 166.49 | 184.94 | 81.1 | 241.69 | 239.8 | 278.35 | 416.29 | 399.28 |
Total Non-Current Liabilities | 7.43M | 4.79M | 7.29M | 11.19M | 5.09M | 6.26M | 8.2M | 6.41M | 2.45M | 4.84M |
Long-Term Debt | 4.83M | 2.65M | 407K | 3.08M | 1.99M | 3.77M | 4.83M | 3.85M | 945K | 520K |
Capital Lease Obligations | 0 | 0 | 711K | 233K | 0 | 1.09M | 723K | 452K | 0 | 716K |
Deferred Tax Liabilities | 1.65M | 585K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.79M | 652K | 4.38M | 6.08M | 1.62M | 374K | 471K | 182K | 1.5M | 2.94M |
Total Liabilities | 16.6M | 14.93M | 15.12M | 16.16M | 11.95M | 15.46M | 16.31M | 13.95M | 11.08M | 13.93M |
Total Debt | 7M | 4.98M | 3.89M | 3.86M | 2.22M | 7.5M | 7.17M | 5.98M | 2.64M | 4.32M |
Net Debt | -20.81M | -2.67M | -6.98M | -9.01M | -38.18M | -13.02M | -1.47M | -510K | 1.47M | 324K |
Debt / Equity | 0.33x | 1.83x | 0.57x | 0.87x | 0.06x | 0.29x | 0.57x | 0.47x | 0.29x | 0.75x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.30x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Interest Coverage | -43.94x | -43.99x | -30.59x | -112.85x | -85.41x | -95.67x | -49.32x | -41.12x | -36.85x | -20.44x |
Total Equity | 21.39M▲ 0% | 2.73M▼ 87.2% | 6.8M▲ 149.2% | 4.43M▼ 34.8% | 37.22M▲ 739.4% | 25.44M▼ 31.6% | 12.61M▼ 50.5% | 12.71M▲ 0.8% | 9.03M▼ 29.0% | 5.74M▲ 0% |
Equity Growth % | 227.53% | -87.25% | 149.16% | -34.77% | 739.4% | -31.64% | -50.45% | 0.8% | -28.96% | -128.01% |
Book Value per Share | 9.01 | 0.67 | 1.42 | 0.62 | 3.03 | 1.96 | 0.91 | 0.63 | 3.72 | 1.61 |
Total Shareholders' Equity | 21.39M | 2.73M | 6.8M | 4.43M | 37.22M | 25.44M | 12.61M | 12.71M | 9.03M | 5.74M |
Common Stock | 60K | 63K | 87K | 8K | 13K | 13K | 15K | 22K | 37K | 37K |
Retained Earnings | -144.15M | -171.15M | -183.28M | -199.1M | -208.87M | -223.95M | -239.15M | -250.47M | -262.4M | -269.28M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -340K | -92K | 50K | -847K | -17K | 563K | 156K | 957K | -692K | -482K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EKSO Cash Flow Statement
Ekso Bionics Holdings, Inc. (EKSO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -31.23M | -22.16M | -15.77M | -8.76M | -11.16M | -14.69M | -12.05M | -9.85M | -11.8M | -11.96M |
Operating CF Margin % | -424.67% | -195.6% | -113.33% | -98.57% | -99.2% | -113.75% | -65.94% | -54.93% | -92.2% | - |
Operating CF Growth % | -24.92% | 29.02% | 28.84% | 44.49% | -27.42% | -31.66% | 17.93% | 18.32% | -19.86% | -229.78% |
Net Income | -29.12M | -26.99M | -12.13M | -15.82M | -9.76M | -15.08M | -15.2M | -11.33M | -11.7M | -15.69M |
Depreciation & Amortization | 1.73M | 1.51M | 690K | 620K | 561K | 887K | 1.7M | 1.61M | 1.57M | 1.65M |
Stock-Based Compensation | 2.92M | 3.08M | 2.4M | 2.58M | 2.5M | 2.73M | 2.24M | 1.63M | 1.47M | 1.34M |
Deferred Taxes | -3.24M | -606K | -5.87M | 2.43M | -4.12M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 55K | 308K | 1.16M | 319K | 134K | -647K | -207K | 771K | -1.11M | 3.53M |
Working Capital Changes | -3.58M | 530K | -2.02M | 1.12M | -468K | -2.58M | -583K | -2.52M | -2.04M | -2.79M |
Change in Receivables | -1.08M | -850K | -1.6M | 1.75M | -1.62M | -67K | -1.21M | -1.97M | 446K | 1.97M |
Change in Inventory | -2.1M | -1.66M | 893K | 379K | -752K | -1.4M | 232K | 257K | -275K | 272K |
Change in Payables | 77K | 752K | -1.23M | -402K | 1.61M | -102K | -1.31M | -288K | -137K | 98K |
Cash from Investing | -456K | -131K | -60K | 0 | -59K | -5.17M | -157K | -37K | -188K | -178K |
Capital Expenditures | -456K | -131K | -60K | 0 | -59K | -194K | -157K | -37K | -188K | -40K |
CapEx % of Revenue | 6.2% | 1.16% | 0.43% | - | 0.52% | 1.5% | 0.86% | 0.21% | 1.47% | 0.35% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -5M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 19K | 0 | 0 | 0 | -138K |
Cash from Financing | 42.57M | 2.27M | 19.04M | 10.7M | 38.71M | 0 | 348K | 7.77M | 6.63M | 8.05M |
Debt Issued (Net) | -54K | -2.17M | -2.38M | 288K | 0 | 0 | -313K | -1.25M | -1.32M | -1.01M |
Equity Issued (Net) | 42.46M | 4.45M | 21.19M | 7.08M | 37.3M | 0 | 661K | 9.02M | 4.1M | 256K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -226K | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 159K | 1K | 228K | 3.33M | 1.42M | 0 | 0 | 0 | 4.08M | 8.81M |
Net Change in Cash | 10.97M▲ 0% | -20.16M▼ 283.8% | 3.22M▲ 116.0% | 1.99M▼ 38.1% | 27.54M▲ 1284.1% | -19.88M▼ 172.2% | -11.89M▲ 40.2% | -2.15M▲ 82.0% | -5.32M▼ 148.2% | -4.06M▲ 0% |
Free Cash Flow | -31.68M▲ 0% | -22.3M▲ 29.6% | -15.83M▲ 29.0% | -8.76M▲ 44.7% | -11.21M▼ 28.1% | -14.88M▼ 32.7% | -12.21M▲ 17.9% | -9.88M▲ 19.1% | -11.99M▼ 21.3% | -11.96M▲ 0% |
FCF Margin % | -430.87% | -196.75% | -113.76% | -98.57% | -99.72% | -115.26% | -66.8% | -55.14% | -93.67% | -103.41% |
FCF Growth % | -21.42% | 29.63% | 28.99% | 44.7% | -28.1% | -32.7% | 17.95% | 19.06% | -21.31% | -42.81% |
FCF per Share | -13.35 | -5.46 | -3.30 | -1.22 | -0.91 | -1.15 | -0.88 | -0.49 | -4.94 | -3.36 |
FCF Conversion (FCF/Net Income) | 1.07x | 0.82x | 1.30x | 0.55x | 1.14x | 0.97x | 0.79x | 0.87x | 1.01x | 0.76x |
Interest Paid | 429K | 457K | 309K | 109K | 104K | 126K | 191K | 182K | 0 | 42K |
Taxes Paid | 20K | 18K | 23K | 6K | 1K | 13K | 45K | 8K | 0 | 4K |
EKSO Key Ratios
Ekso Bionics Holdings, Inc. (EKSO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -208.6% | -223.82% | -254.74% | -281.81% | -46.88% | -48.13% | -79.89% | -89.52% | -107.62% | -177.4% |
Return on Invested Capital (ROIC) | - | -6385.04% | - | - | - | -203.67% | -96.22% | -67.24% | -88.09% | -123.66% |
Gross Margin | 28.14% | 38.03% | 48.6% | 57.08% | 60.01% | 48.13% | 49.67% | 53.06% | 53.48% | 52.86% |
Net Margin | -396.06% | -238.19% | -87.17% | -178.17% | -86.82% | -116.79% | -83.14% | -63.21% | -91.37% | -135.66% |
Debt / Equity | 0.33x | 1.83x | 0.57x | 0.87x | 0.06x | 0.29x | 0.57x | 0.47x | 0.29x | 0.75x |
Interest Coverage | -43.94x | -43.99x | -30.59x | -112.85x | -85.41x | -95.67x | -49.32x | -41.12x | -36.85x | -20.44x |
FCF Conversion | 1.07x | 0.82x | 1.30x | 0.55x | 1.14x | 0.97x | 0.79x | 0.87x | 1.01x | 0.76x |
Revenue Growth | -48.29% | 54.11% | 22.81% | -36.18% | 26.62% | 14.81% | 41.57% | -1.94% | -28.6% | -34.08% |
Related:EKSO Dividend History·EKSO Revenue History·EKSO Price History·EKSO P/E History·EKSO Financial Ratios·EKSO Institutional Holders
EKSO SEC Filings & Documents
Ekso Bionics Holdings, Inc. (EKSO) SEC filings — annual & quarterly reports (10-K, 10-Q)
EKSO Frequently Asked Questions
Ekso Bionics Holdings, Inc. (EKSO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ekso Bionics Holdings, Inc. (EKSO) reported $11.6M in revenue for fiscal year 2025. This represents a 250% increase from $3.3M in 2013.
Ekso Bionics Holdings, Inc. (EKSO) saw revenue decline by 28.6% over the past year.
Ekso Bionics Holdings, Inc. (EKSO) reported a net loss of $15.7M for fiscal year 2025.
Dividend & Returns
Yes, Ekso Bionics Holdings, Inc. (EKSO) pays a dividend with a yield of 0.40%. This makes it attractive for income-focused investors.
Ekso Bionics Holdings, Inc. (EKSO) has a return on equity (ROE) of -107.6%. Negative ROE indicates the company is unprofitable.
Ekso Bionics Holdings, Inc. (EKSO) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.